Predictors of Skeletal-Related Events among Cancer Patients with Bone Metastases Treated with Zoledronic Acid: a Secondary Analysis of a Randomized Study.
CONCLUSION: Among advanced cancer patients with bone metastases, lytic nature of metastases, as well as higher body mass index, are associated with a higher probability of SREs.
TRIAL REGISTRATION NUMBER: This clinical trial was registered at clinicaltrials.gov with the number: NCT0033.
PMID: 29972647 [PubMed - as supplied by publisher]
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Reclast | Study | Zometa